- 3-Trimethylammoniumphenyl N,N-dimethylcarbamate
- Benzenaminium, 3-[[(dimethylamino)carbonyl]oxy]-N,N,N-trimethyl-
Registry Numbers and Inventories.
Japan ENCS (MITI)
Hazards and Protection.
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Strong oxidizing agents.
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.
Abnormally low blood pressure may occur from peripheral actions. However, elevated blood pressure may also be seen secondary to the anxiety resulting from the effects on other organ systems. Likewise, bradyarrhythmias are common from the antimyasthenics, but rapid heart rate may occur secondary to the anxiety resulting from the effects on other organ systems. Respiratory rate may be increased in patients with airway compromise. seizures and coma have been described; profound weakness and muscle fasciculations may also occur. In less severe cases, headache, dizziness, and dysarthria may occur. Parkinsonian-like symptoms have been reported during therapeutic use of pyridostigmine.
Cramping, abdominal pain, hyperperistalsis, vomiting, and diarrhea have been described.
Excess secretions in the tracheal tree, bronchospasm, and pulmonary edema may occur.
Dermatitis, urticaria and reversible alopecia have been reported.
Constriction of the pupil, blurred vision, and excessive secretions in the nose and throat may be present.
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
Remove contaminated clothing. Wash exposed area with soap and water. If symptoms persist, seek medical attention. Launder clothing before reuse.
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.